| Literature DB >> 31571667 |
Si-Qun Jing1, Sai-Sai Wang2, Rui-Min Zhong1, Jun-Yan Zhang1, Jin-Zi Wu3, Yi-Xian Tu4, Yan Pu4, Liang-Jun Yan3.
Abstract
Orientin is a flavonoid monomer. In recent years, its importance as a source of pharmacological active substance is growing rapidly due to its properties such as anti-myocardial ischemia, anti-apoptosis, anti-radiation, anti-tumor, and anti-aging. However, the neuroprotective effects of Orientin on stroke injury have not been comprehensively evaluated. The aim of the present study was thus to investigate the neuroprotective capacity and the potential mechanisms of Cyperus esculentus L. orientin (CLO) from Cyperus esculentus L. leaves against ischemia/reperfusion (I/R) injury using standard orientin as control. For in vitro studies, we treated HT22 cells with CoCl2 as an in vitro ischemic injury model. HT22 cells in the control group were treated with CoCl2. For in vivo studies, we used rat models of middle cerebral artery occlusion, and animals that received sham surgery were used as controls. We found that CLO protected CoCl2-induced HT22 cells against ischemia/reperfusion injury by lowering lipid peroxidation and reactive oxygen species formation as well as decreasing protein oxidation. However, CLO did not reduce the release of lactate dehydrogenase nor increase the activity of superoxide dismutase. Results showed that CLO could decrease neurological deficit score, attenuate brain water content, and reduce cerebral infarct volume, leading to neuroprotection during cerebral ischemia-reperfusion injury. Our studies indicate that CLO flavonoids can be taken as a natural antioxidant and bacteriostastic substance in food and pharmaceutical industry. The molecular mechanisms of CLO could be at least partially attributed to the antioxidant properties and subsequently inhibiting activation of casepase-3. All experimental procedures and protocols were approved on May 16, 2016 by the Experimental Animal Ethics Committee of Xinjiang Medical University of China (approval No. IACUC20160516-57).Entities:
Keywords: Cyperus esculentus L. orientin (CLO); antioxidants; caspase-3; cerebral ischemia/reperfusion injury; cobalt chloride; lipid peroxidation; nerve regeneration; neurological deficits; oxidative stress; reactive oxygen species
Year: 2020 PMID: 31571667 PMCID: PMC6921342 DOI: 10.4103/1673-5374.266063
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
Cyperus esculentus L. orientin increases neurological score of rats at 24 hours after ischemia/reperfusion injury
| Group | Score |
|---|---|
| Sham | 0 |
| Model | 2.0±0.55††† |
| Positive control 1 (20 mg/kg) | 1.42±0.67†††### |
| Positive control 2 (0.3 tablet/kg) | 1.33±0.52†††### |
| High-dose intervention (500 mg/kg) | 1.25±0.42†††### |
| Low-dose intervention (125 mg/kg) | 1.33±0.52†††### |
###P < 0.001, vs. model group; †††P < 0.001, vs. sham group. Data are presented as the mean ± SD (n = 6, Mann-Whitney U Test).
Cyperus esculentus L. orientin attenuates the brain water content of rats after I/R
| Group | Brain water content in the left hemisphere (%) | Brain water content in the right hemisphere (%) |
|---|---|---|
| Sham | 0.8148±0.0036 | 81.31 ±0.0087 |
| Model | 0.8186±0.0006 | 83.42 ±0.0047††† |
| Positive control 1 (20 mg/kg) | 0.8165±0.0009 | 82.08±0.0050### |
| Positive control 2 (0.3 tablet/kg) | 0.8173±0.0015 | 80.81±0.0020### |
| High-dose intervention (500 mg/kg) | 0.8144±0.0018 | 82.24 ±0.0053##† |
| Low-dose intervention (125 mg/kg) | 0.8154±0.0052 | 82.25 ±0.0086##† |
##P < 0.01, ###P < 0.001, vs. model group; †P < 0.05, †††P < 0.001, vs. sham group. Data are presented as the mean ± SD (n = 6, one-way analysis of variance followed by Tukey post hoc test).
Cyperus esculentus L. orientin attenuates the cerebral infarct volume of rats after ischemia/reperfusion injury
| Group | Cerebral infarct volume (%) |
|---|---|
| Sham | 0 |
| Model | 19.23±4.56 |
| Positive control 1 (20 mg/kg) | 10.23±3.76†† |
| Positive control 2 (0.3 tablet/kg) | 15.23±3.85† |
| High-dose intervention (500 mg/kg) | 13.23±4.10†† |
| Low-dose intervention (125 mg/kg) | 14.93±4.43† |
†P < 0.05, ††P < 0.01, vs. sham group. Data are presented as the mean ± SD (n = 6, one-way analysis of variance followed by Tukey post hoc test).